Craig Hofmeister's guest appearances

Craig Hofmeister

CureTalks

HealthTree Podcast for Multiple Myeloma

Johns Hopkins

Stephen Russell

Adam Cohen

David Siegel

Mike Thompson

Beth Israel

Damian Green

Sarah Cannon

Keith Stewart

Mark Newman

Paul Richardson

Stephen Harding

Kenneth Anderson

Vincent Rajkumar

Thomas Martin

OwlTail

Join us for this first interview on Myeloma Crowd Radio highlighting new Myeloma Crowd Research Initiative on high-risk myeloma. For the first time, patients and doctors are joining together to find and fund research for patient group that is desperate for new options. The MCRI initiative reached out the the worldwide community and asked them to submit their research proposals for high-risk patients. We received 36 high quality proposals from all over the world. The MCRI Scientific Advisory Board then scored the proposals, selecting 10 for further review. These ten will be included in the Myeloma Crowd Radio/MCRI series on high-risk.  As part of this series, Dr. Craig Hofmeister, MD from Ohio State University will share his research being done to use engineered CAR T cells to specifically target the high-risk types of multiple myeloma. Thanks to our episode sponsor, Takeda Oncology.

Join us for this first interview on Myeloma Crowd Radio highlighting new Myeloma Crowd Research Initiative on high-risk myeloma. For the first time, patients and doctors are joining together to find and fund research for patient group that is desperate for new options. The MCRI initiative reached out the the worldwide community and asked them to submit their research proposals for high-risk patients. We received 36 high quality proposals from all over the world. The MCRI Scientific Advisory Board then scored the proposals, selecting 10 for further review. These ten will be included in the Myeloma Crowd Radio/MCRI series on high-risk.  <br><br>As part of this series, Dr. Craig Hofmeister, MD from Ohio State University will share his research being done to use engineered CAR T cells to specifically target the high-risk types of multiple myeloma. <br><br>Thanks to our episode sponsor, Takeda Oncology.

Myeloma Crowd Radio/MCRI: Dr. Craig Hofmeister, MD, OSU, CAR T cells